Digest Réseau Comment ça marche
Réseau
/
Sociétés
Te
Non vérifié

Teva Pharmaceutical Industries Ltd

Ce que nous écrivons

Annonces ÉconomiquesFinanceIndustrie pharmaceutiqueManagement/Organisation d'EntrepriseMédecine Santé Bien-être

132 communiqués de presse

Voir tous les communiqués de presse
30/09/2026
Industrie pharmaceutique
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
Source
Teva Pharmaceutical Industries Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
28/09/2026
Industrie pharmaceutique
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Source
Teva Pharmaceutical Industries Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
23/09/2026
Industrie pharmaceutique
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
Source
Teva Pharmaceutical Industries Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
23/09/2026
Industrie pharmaceutique
Teva Releases Q3 2026 Aide Memoire
Source
Teva Pharmaceutical Industries Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
18/09/2026
Industrie pharmaceutique
Médecine Santé Bien-être
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Source
Teva Pharmaceutical Industries Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
18/09/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Source
Teva Pharmaceutical Industries Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
18/09/2026
Industrie pharmaceutique
Annonces Économiques
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Source
Teva Pharmaceutical Industries Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
16/09/2026
Industrie pharmaceutique
Médecine Santé Bien-être
Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
Source
Teva Pharmaceutical Industries Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
14/09/2026
Industrie pharmaceutique
Finance
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
Source
Teva Pharmaceutical Industries Ltd
Émetteur
GLOBENEWSWIRE
1.00
0
10/09/2026
Industrie pharmaceutique
Fonds d'investissement
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
Source
Teva Pharmaceutical Industries Ltd
Émetteur
GLOBENEWSWIRE
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0